Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells

Experimental Hematology

Volumn 35, Issue 10, 2007, Pages 1510-1521

  Gleixner, Karoline V ^a   Rebuzzi, Laura ^a,b   Mayerhofer, Matthias ^a   Gruze, Alexander ^c   Hadzijusufovic, Emir ^a,b   Sonneck, Karoline ^a   Vales, Anja ^a   Kneidinger, Michael ^a   Samorapoompichit, Puchit ^d   Thaiwong, Tuddow ^e   Pickl, Winfried F ^c   Yuzbasiyan Gurkan, Vilma ^e   Sillaber, Christian ^a   Willmann, Michael ^b   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Medical University of Vienna Institute of Histology and Embryology   (Austria)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; MIDOSTAURIN; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; FLOW CYTOMETRY; GROWTH INHIBITION; IC 50; IN VITRO STUDY; MASTOCYTOMA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HEMATOLOGIC NEOPLASMS; HUMANS; MAST CELLS; MAST-CELL SARCOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 34548687030     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.06.005     Document Type: Article

References (58)

1. Macy D.W. Canine mast cell tumors. Vet Clin North Am Small Anim Pract 15 (1985) 783-803
2. London C.A., and Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 33 (2003) 473-489
3. Misdorp W. Mast cells and canine mast cell tumours. A review. Vet Q 26 (2004) 156-169
4. Lennert K., and Parwaresch M.R. Mast cells and mast cell neoplasia: a review. Histopathology 3 (1979) 349-365
5. Metcalfe D.D. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 96 Suppl (1991) 2S-4S
6. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 108 (1996) 385-397
7. Valent P., Akin C., Sperr W.R., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122 (2003) 695-717
8. Akin C., and Metcalfe D.D. Systemic mastocytosis. Annu Rev Med 55 (2004) 419-432
9. Valent P., Ghannadan M., Akin C., et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 34 (2004) 41-52
10. v mice and their increase by bone marrow transplantation. Blood 52 (1978) 447-452
11. Furitsu T., Tsujimura T., Tono T., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest 92 (1993) 1736-1744
12. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92 (1995) 10560-10564
13. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12 (1996) 312-314
14. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc Natl Acad Sci U S A 96 (1999) 1609-1614
15. Fritsche-Polanz R., Jordan J.H., Feix A., et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 113 (2001) 357-364
16. Feger F., Ribadeau Dumas A., Leriche L., Valent P., and Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 127 (2002) 110-114
17. London C.A., Galli S.J., Yuuki T., et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27 (1999) 689-697
18. Jones C.L., Grahn R.A., Chien M.B., et al. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest 16 (2004) 95-100
19. Zemke D., Yamini B., and Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 39 (2002) 529-535
20. Riva F., Brizzola S., Stefanello D., et al. A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest 17 (2005) 385-388
21. Mauro M.J., and Druker B.J. STI571: a gene product-targeted therapy for leukemia. Curr Oncol Rep 3 (2001) 223-227
22. Deininger M.W., and Druker B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55 (2003) 401-423
23. Pardanani A., and Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104 (2004) 1931-1939
24. Frost M.J., Ferrao P.T., Hughes T.P., and Ashman L.K. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1 (2002) 1115-1124
25. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit. Exp Hematol 31 (2003) 686-692
26. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations. Blood 99 (2002) 1741-1744
27. Akin C., Fumo G., Yavuz A.S., Lipsky P.E., Neckers L., and Metcalfe D.D. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103 (2004) 3222-3225
28. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 (2005) 721-724
29. Gotlib J., Berube C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106 (2005) 2865-2870
30. von Bubnoff N., Gorantla S.H., Kancha R.K., Lordick F., Peschel C., and Duyster J. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19 (2005) 1670-1671
31. Gleixner K.V., Mayerhofer M., Aichberger K.J., et al. The tyrosine kinase-targeting drug PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of kit: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 107 (2006) 752-759
32. Shah N.P., Lee F.Y., Luo R., Jiang Y., Donker M., and Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 108 (2006) 286-291
33. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66 (2006) 473-481
34. Fabbro D., Ruetz S., Bodis S., et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15 (2000) 17-28
35. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
36. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
37. DeVinney R., and Gold W.M. Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol 3 (1990) 413-420
38. Valent P., Ashman L.K., Hinterberger W., et al. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73 (1989) 1778-1785
39. Rebuzzi L., Willmann M., Sonneck K., et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 115 (2007) 320-333
40. Agis H., Krauth M.T., Böhm A., et al. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol 125 (2006) 273-281
41. Sillaber C., Gesbert F., Frank D.A., Sattler M., and Griffin J.D. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95 (2000) 2118-2125
42. Bühring H.J., Ashman L.K., Gattei V., et al. Stem-cell factor receptor (p145(c-kit)) summary report (CD117). In: Schlossmann S.F., Boumsell L., and Gilks W. (Eds). Leucocyte Typing V. White Cell Differentiation Antigens (1995), Oxford University Press, Oxford, UK 1882-1888
43. Van Cruchten S., and Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 31 (2002) 214-223
44. Reguera M.J., Rabanal R.M., Puigdemont A., et al. Canine mast cell tumors express stem cell factor receptor. Am J Dermatopathol 22 (2000) 49-54
45. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Hematologica. In press.
46. Butterfield J.H., Weiler D., Dewald G., and Gleich G.J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 12 (1988) 345-355
47. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link?. Immunol Today 15 (1994) 111-114
48. Escribano L., Orfao A., Diaz-Agustin B., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 91 (1998) 2731-2736
49. Ma Y., Longley B.J., Wang X., Blount J.L., Langley K., and Caughey G.H. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 112 (1999) 165-170
50. Webster J.D., Yuzbasiyan-Gurkan V., Miller R.A., Kaneene J.B., and Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol 44 (2007) 298-308
51. Jiang X., Zhao Y., Smith C., et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21 (2007) 926-935
52. Weisberg E.L., Catley L., Wright R.D., et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR/ABL+ leukemias. Blood 109 (2007) 2112-2120
53. Bradeen H.A., Eide C.A., O'Hare T., et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108 (2006) 2332-2338
54. Khanna C., Lindblad-Toh K., Vail D., et al. The dog as a cancer model. Nat Biotechnol 24 (2006) 1065-1066
55. Porrello A., Cardelli P., and Spugnini E.P. Oncology of companion animals as a model for humans. An overview of tumor histotypes. J Exp Clin Cancer Res 25 (2006) 97-105
56. London C.A., Hannah A.L., Zadovoskaya R., et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9 (2003) 2755-2768
57. Cohen M.H., Williams G., Johnson J.R., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8 (2002) 935-942
58. Patnaik A.K., Ehler W.J., and MacEwen E.G. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 21 (1984) 469-474